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Key facts 
• In 2017, 31 273 cases of hepatitis C were reported in 29 EU/EEA Member States. Excluding countries 
that only reported acute cases, 31 178 cases corresponds to a crude rate of 7.3 cases per 100 000 
population. 
• Of the cases reported, 3% were classified as acute, 22% as chronic and 75% as ‘unknown’. 
• Hepatitis C was more commonly reported among men than women, with a male-to-female ratio of 
1.6:1. The most affected age group among males was between 35–44 years and for females between 
25–34 years. 
• Mode of transmission was reported for 26% of cases. The most commonly reported mode was injecting 
drug use, which accounted for 44% of cases with complete information on transmission status. 
• The interpretation of hepatitis C notification data across countries remains problematic, with ongoing 
differences in surveillance systems and difficulties in defining reported cases as acute or chronic. With 
hepatitis C, a largely asymptomatic disease until the late stages, surveillance based on notification data 
is challenging, with data reflecting testing practices rather than true occurrence of disease. 
Methods 
This report is based on 2017 data retrieved from The European Surveillance System (TESSy) on 10 December 2018. 
TESSy is a system for the collection, analysis and dissemination of data on communicable diseases. 
For a detailed description of methods used to produce this report, refer to the Methods chapter [1]. 
An overview of the national surveillance systems is available on the ECDC website [2]. 
A subset of the data used for this report is available through ECDC’s online Surveillance atlas of infectious 
diseases [3]. 
This report includes data on newly diagnosed cases of hepatitis C virus (HCV) infection reported to ECDC by 
EU/EEA countries. Countries were requested to apply the EU 2012 case definition for reporting at the European 
level1, but other case definitions were also accepted. 
 
 
                                                                                                                         
 
1 2012/506/EC: Commission Implementing Decision of 8 August 2012 amending Decision 2002/253/EC laying down case 
definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European 
Parliament and of the Council. 
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Acute and chronic hepatitis C infections were differentiated by countries using defined criteria (Table 1). 
Table 1. Criteria for differentiating acute and chronic hepatitis C 
Stage Definition 
Acute 
Recent HCV seroconversion (prior negative test for hepatitis C in last 12 months) 
or 
Detection of hepatitis C virus nucleic acid (HCV RNA) or hepatitis C virus core antigen (HCV-core) in serum/plasma 
and no detection of hepatitis C virus antibody (negative result) 
Chronic Detection of hepatitis C virus nucleic acid (HCV RNA) or hepatitis C core antigen (HCV-core) in serum/plasma in two samples taken at least 12 months apart* 
Unknown Any newly diagnosed case which cannot be classified in accordance with the above description of acute or chronic infection 
*: in the event that the case was not notified the first time. 
Surveillance systems across the EU/EEA countries are heterogeneous. Twenty countries submitted national data in 
2017 based on the 2012 EU case definition1, five countries used the 2008 EU case definition and four countries 
used national case definitions. The EU 2012 case definition is similar to the EU 2008 case definition, but includes 
detection of hepatitis C core antigen as an additional diagnostic criterion. Both case definitions capture all acute 
and chronic laboratory-diagnosed cases of hepatitis C. All reported cases were included in the analysis regardless 
of which case definition was used. Data collected represent confirmed cases. Three countries, Hungary, Lithuania 
and the Netherlands, only submitted data on acute cases of hepatitis C. 
Hepatitis C data are presented by the ‘date of diagnosis’ or, if not available, ‘date used for statistics’. 
Italy reported using two data sources. One has national coverage, but includes only a limited number of variables 
and was used for the calculation of national rates and analysis by age and gender. The other is a voluntary 
reporting system of acute cases and covers 78% of the population in 2017. The sentinel population is considered 
representative of the wider population and data were therefore scaled up to 100%. This data source contains 
information on a range of variables and is used for certain epidemiological analyses, including the route of 
transmission and importation status. The data source for Belgium is a sentinel system with unknown population 
coverage. National rates were therefore not calculated for Belgium. 
Epidemiology 
Overall trends 
For 2017, 29 EU/EEA Member States reported 31 273 cases of HCV infection. Excluding the three countries that 
only report acute cases (Hungary, Lithuania and the Netherlands), the total number of cases (31 178) represents a 
decrease of 9.8% over the previous year (Table 2). No data were reported from France or Liechtenstein. Of all 
cases reported, 861 (2.8%) were reported as acute, 6 805 (21.8%) as chronic, 23 311 (74.8%) as ‘unknown’ and 
296 cases (0.9%) could not be classified due to an incompatible data format. Excluding countries that only 
reported acute cases, the crude rate of HCV infection was 7.3 per 100 000 population in 2017. From 2008–2017, 
the overall number of cases diagnosed and reported across the 22 EU/EEA Member States that reported data 
consistently over this time, excluding those who only reported acute cases, showed year-to-year fluctuations, 
increasing from 2010–2014 to a high of 9.8 cases per 100 000 population and decreasing again slightly since then 
(Figure 1). 
Country-specific rates ranged from 0.3 cases per 100 000 population in Italy to 71.5 cases per 100 000 population 
in Latvia (Table 2). The United Kingdom accounted for 34% of all reported cases. 
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Table 2. Number and rate per 100 000 of reported hepatitis C cases in the EU/EEA by country and 
year, 2013–2017* 
Country 
2013 2014 2015 2016 2017 
All All All All All Acute† Chronic† Unknown† 
Cases Rate Cases Rate Cases Rate Cases Rate Cases Rate Cases Rate Cases Rate Cases Rate 
Austria 899 10.6 1 843 21.7 1 469 17.1 1 401 16.1 1 285 14.6 79 0.9 563 6.4 643 7.3 
Belgium 981 - 1 062 - 1 356 - 1 603 - 1 519 - . - . - 1 519 - 
Bulgaria 95 1.3 90 1.2 85 1.2 81 1.1 84 1.2 . - . - . - 
Croatia 202 4.7 144 3.4 155 3.7 184 4.4 212 5.1 . - . - . - 
Cyprus 36 4.2 30 3.5 2 0.2 1 0.1 21 2.5 . - 21 2.5 0 0.0 
Czech Republic 930 8.8 887 8.4 972 9.2 1069 10.1 932 8.8 112 1.1 820 7.8 . - 
Denmark 278 5.0 272 4.8 276 4.9 200 3.5 138 2.4 10 0.2 128 2.2 0 0.0 
Estonia 276 20.9 334 25.4 257 19.5 178 13.5 121 9.2 6 0.5 115 8.7 . - 
Finland 1 172 21.6 1 224 22.5 1 164 21.3 1 147 20.9 1 115 20.3 . - . - 1 115 20.3 
Germany1 5 178 6.4 5 866 7.3 4 928 6.1 4 402 5.4 4 777 5.8 . - . - 4 777 5.8 
Greece 22 0.2 18 0.2 14 0.1 80 0.7 152 1.4 4 0.0 148 1.4 . - 
Hungary2 . - . - . - . - . - 11 0.1  - . - 
Iceland 72 22.4 38 11.7 44 13.4 91 27.4 95 28.1 2 0.6 57 16.8 36 10.6 
Ireland 779 16.9 703 15.2 675 14.4 643 13.6 611 12.8 29 0.6 99 2.1 483 10.1 
Italy 199 0.3 200 0.3 207 0.3 194 0.3 182 0.3  -  - 182 0.3 
Latvia 1 369 67.6 1 804 90.1 1 970 99.2 1 812 92.0 1 394 71.5 41 2.1 1 353 69.4 . - 
Lithuania2 . - . - . - . - . - 25 0.9  - . - 
Luxembourg 68 12.7 68 12.4 58 10.3 58 10.1 95 16.1 . - 0 0.0 95 16.1 
Malta 14 3.3 14 3.3 10 2.3 13 2.9 18 3.9 1 0.2 5 1.1 12 2.6 
Netherlands2 . - . - . - . - . - 59 0.3 . - . - 
Norway 1 318 26.1 1 213 23.7 1 186 23.0 771 14.8 656 12.5 . - . - 656 12.5 
Poland 2 644 6.9 3 552 9.3 4 285 11.3 4 261 11.2 4 010 10.6 7 0.0 750 2.0 3 253 8.6 
Portugal 27 0.3 86 0.8 261 2.5 344 3.3 230 2.2 36 0.3 112 1.1 82 0.8 
Romania 127 0.6 104 0.5 60 0.3 73 0.4 70 0.4 67 0.3 3 0.0 . - 
Slovakia 314 5.8 397 7.3 334 6.2 268 4.9 152 2.8 16 0.3 136 2.5 . - 
Slovenia 89 4.3 64 3.1 65 3.2 115 5.6 117 5.7 6 0.3 111 5.4 . - 
Spain . - . - 756 1.6 790 1.7 892 1.9 189 0.4 131 0.3 572 1.2 
Sweden 2015 21.1 1 830 19.0 1 902 19.5 1 831 18.6 1 664 16.6 153 1.5 1 185 11.9 326 3.3 
United Kingdom 13 757 21.5 14 028 21.8 13 559 20.9 12 991 19.9 10 636 16.2 8 0.0 1 068 1.6 9 560 14.5 
Total EU/EEA 32 861 8.9 35 871 9.7 36 050 8.5 34 601 8.1 31 178 7.3 861 0.3 6 805 2.8 23 311 6.3 
*: data presented by date of diagnosis 
†: includes cases reported by countries as acute, chronic or unknown using differentiation criteria 
-: rate not calculated 
.: data not reported 
1: Germany uses national case definition that changed in 2015, likely explaining recent decrease in cases. 
2: ’All cases’ not displayed for countries that only report acute cases. 
Twenty countries were able to provide data on acute cases (Table 2). The rate of reported acute cases was 0.3 per 
100 000 population, ranging from <0.1 in Greece, Poland and the United Kingdom to 2.1 per 100 000 in Latvia. 
Nineteen countries submitted data on chronic infections. The notification rate of chronic cases was 2.8 cases per 
100 000 population, ranging from <0.1 in Luxembourg and Romania to 69.4 in Latvia. The rate of cases classified 
as unknown ranged from <0.1 cases per 100 000 population in Cyprus and Denmark to 20.3 in Finland. Overall 
notification rates were mostly higher in northern and western European countries than in southern European 
countries (Figure 2). 
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Figure 1. Notification rate of hepatitis C cases per 100 000 population by year, EU/EEA, 2008–2017, 
among countries reporting consistently excluding countries that only reported acute cases 
 
Source: Country reports from Austria, Bulgaria, Cyprus, the Czech Republic, Denmark, Estonia, Finland, Germany, Greece, 
Iceland, Ireland, Italy, Latvia, Luxembourg, Malta, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Sweden and the 
United Kingdom. 
0
2
4
6
8
10
12
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Ra
te
 p
er
 1
00
 0
00
 p
op
ul
at
io
n
 
 
 
 
SURVEILLANCE REPORT Annual epidemiological report for 2017 
 
 
5 
 
 
Figure 2. Notification rate of newly diagnosed hepatitis C cases per 100 000 population by country*, 
EU/EEA, 2017 
 
 
*: Countries not reporting any data or reporting data only on acute cases are excluded from this map. 
Source: Country reports from Austria, Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, Finland, Germany, 
Greece, Iceland, Ireland, Italy, Latvia, Luxembourg, Malta, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden 
and the United Kingdom. 
Age and gender 
In 2017, 20 087 cases were reported in males (9.6 cases per 100 000 population) and 10 740 in females (4.8 cases 
per 100 000 population), excluding countries that only reported acute cases. This corresponds to a male-to-female 
rate of 2.0:1. Rates were higher among males than females for almost all age categories (Figure 3). The age 
distributions among males and females were similar. The most affected age group among males was from 
35–44 years (19.6 cases per 100 000 population) and for females from 25–34 years (9.1 cases per 100 000 
population). Twelve percent of acute cases and 7% of chronic cases were reported in people under 25 years. The 
proportion of all cases under 25 years declined from 12% in 2008 to 6% in 2017. 
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Figure 3. Notification rate of newly diagnosed hepatitis C cases per 100 000 population by age and 
gender, EU/EEA, 2017 
 
Source: Country reports from Austria, Cyprus, the Czech Republic, Denmark, Estonia, Finland, Germany, Greece, Iceland, Ireland, 
Italy, Latvia, Luxembourg, Malta, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the United 
Kingdom. 
Route of transmission 
Data regarding the most likely route of transmission of hepatitis C were complete for 8 129 (26%) cases in 2017. 
The most commonly reported route of transmission across all disease categories was injecting drug use, which 
accounted for 44% of cases with complete information. The percentage of transmission attributable to injecting 
drug use among cases with a known transmission route was lower among acute cases (40%) than among those 
classified as chronic (55%; Figure 4). The second most common route of transmission among acute cases was 
nosocomial, accounting for 17% of acute cases, followed by sex between men (15%). 
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Figure 4. Transmission category of hepatitis C cases by acute and chronic disease status, EU/EEA, 
2017† 
 
†: cases with known transmission status. 
*: ‘Nosocomial transmission’ includes hospital, nursing home, psychiatric institutions and dental. This category refers mainly to 
patients exposed through healthcare settings, distinct from ‘needle-stick and other occupational exposure’, which refers to staff. 
**: ‘Non-occupational injuries’ include needle-sticks that occur outside a healthcare setting, bites, tattoos and piercings. 
***: ‘Needle-stick and other occupational exposure’ refers to occupational injuries. 
Sources 
Acute cases: Country reports from Austria, Denmark, Estonia, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Malta, the 
Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain and Sweden. 
Chronic cases: Country reports from Austria, Cyprus, Denmark, Estonia, Iceland, Ireland, Latvia, Malta, Poland, Portugal, 
Slovakia, Slovenia, Spain and Sweden. 
Importation status 
In 2017, 22 countries provided data for 14 678 cases (46%) on whether a case was considered ‘imported’ from 
outside the reporting country or acquired in the country itself. Of those cases, 1 200 (8%) were reported as 
imported. 
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Discussion 
The number of newly diagnosed hepatitis C cases reported from countries across Europe remains at a high level, with 
considerable variation between country-specific rates. This is consistent with evidence from seroprevalence surveys. 
According to a recent systematic review, 3.9 million individuals are chronically infected with HCV in EU/EEA countries, 
with national estimates of anti-HCV prevalence in the general population ranging from 0.1%–5.9% [4]. The burden of 
disease presents a serious public health challenge for national health systems. While the incidence of new infections 
has declined in many European countries due to implementation of prevention strategies targeting transmission 
through injecting drug use and healthcare and also possibly the impact of the rolling out of programmes to cure the 
infection, modelling suggests that morbidity and mortality will continue to increase [5,6]. 
The number of countries reporting hepatitis C surveillance data has increased in recent years, but data analysis 
and interpretation remain challenging on account of the incompleteness of data and heterogeneity in national 
surveillance systems and practices. While the number of countries using the 2012 EU case definition has increased, 
nine countries still do not use the updated definition, which hampers the ability to compare data across countries. 
Germany uses a national case definition that changed in 2015, likely explaining the recent decrease in cases of 
hepatitis C in Germany. Data completeness for several variables improved in 2017, but remains low. Countries still 
have difficulty defining cases as acute or chronic and the majority of cases reported are classified ‘unknown’. It is 
likely that most ‘unknown’ cases are chronic infections as acute hepatitis C is difficult to diagnose and most cases 
are identified through screening practices. The variation in notification rates between countries is likely related to 
differences in local testing practices as hepatitis C is mostly asymptomatic, so most newly diagnosed cases are 
probably identified through local screening initiatives. Indeed, many northern and western European countries such 
as the United Kingdom, which has extensive testing programmes targeting populations at risk, report the highest 
notification rates in the EU/EEA, but are also known from serosurveys to have low prevalence estimates [4,7]. 
Countries in eastern and south-eastern Europe have the lowest reported rates of cases, but some of the highest 
prevalence estimates. This discrepancy highlights the challenge of interpreting hepatitis C surveillance data that are 
heavily influenced by testing and screening practices and the importance of considering other sources of 
information such as local testing practices and seroprevalence estimates. 
Reported data indicate that hepatitis C is an infection which predominantly affects men aged 25–44 years. This 
profile is consistent with the demographic profile of injecting drug use, the main route of transmission reported. 
Data are consistent with the findings of the recent systematic review of hepatitis C seroprevalence, which found 
that prevalence among people who inject drugs (PWID) in most EU/EEA countries is high (>50%) [4]. Harm 
reduction programmes and more recently treatment with new direct-acting antiviral drugs may have contributed 
significantly to reducing transmission in many countries. However, the burden of infection remains high among 
PWID and evidence of ongoing transmission emphasises the ongoing need for comprehensive harm reduction 
measures targeted at this at-risk population [8,9]. 
Among acute cases, the other main reported routes of transmission included nosocomial transmission and 
transmission among men who have sex with men. Reports of hepatitis C infections among HIV-positive men who 
have sex with men in several European countries since 2000 have resulted in many countries scaling up targeted 
prevention and control responses [10]. Nosocomial transmission remains an uncommon route of transmission in 
most European countries, but is still a key route of transmission among newly diagnosed cases in a few countries, 
highlighting the importance of comprehensive infection prevention and control systems within healthcare. 
The World Health Assembly recently adopted the first Global Health Sector Strategy on Viral Hepatitis aimed at 
eliminating viral hepatitis as a public health threat [11]. The concept of elimination for hepatitis C is based on 
reducing the incidence of chronic infections by 90% and the associated mortality by 65% by 2030. Achieving these 
targets will require a significant scaling-up of key interventions, including interventions aimed at preventing 
transmission among PWID and increased testing with linkage to care and treatment. 
Public health implications 
Hepatitis C is a public health concern across Europe with a high burden of infection and high levels of associated 
morbidity and mortality. The launch of a global strategy aimed at eliminating viral hepatitis provides a much 
welcomed opportunity to increase efforts aimed at tackling this epidemic. To achieve the goal of elimination, it is 
essential that countries have access to robust epidemiological information to plan and monitor effective prevention 
and control programmes. Surveillance data do not provide a clear epidemiological picture and should be carefully 
examined alongside information on local screening practices and available seroprevalence data. Further 
improvements to the quality of hepatitis C surveillance data are important to increase data utility and ECDC is 
working closely with Member States to improve local surveillance systems. ECDC is also developing alternative 
epidemiological data sources, including the generation of prevalence estimates using standardised methodologies. 
Despite the limitations of routine surveillance for hepatitis C, data clearly indicate that a high proportion of 
reported cases are attributed to injecting drug use, highlighting the importance of harm reduction measures. 
Ongoing nosocomial transmission and transmission among men who have sex with men in the region suggests the 
need to implement targeted and comprehensive public health programmes tailored to the local epidemiology. 
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